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INTRODUCTION
Anticoagulant therapy isknown tobeoneof the causes
of retroperitoneal hematoma (1-5). The mortality rate
of patients with retroperitoneal hematoma who have
undergone anticoagulant therapy has been reported to
be higher than that of patients who have not undergone
anticoagulant therapy (1). It has also been reported that
the combination of warfarin, an anticoagulant drug, and
5-FU can prolong coagulation time (6 -10).
We describe two cases of retroperitoneal hematoma
in patients who underwent combination therapy with
anticoagulant drugs and 5-FU. CT scans showed char-
acteristic findings of hematoma and were useful to
know the extent of the hematoma.
CASE REPORT
Patient 1 :
A 71-year-old male was admitted to our institute
with increasing dyspnea and hoarseness. He had been
treated for chronic heart failure and had undergone
total esophageal resection for esophageal cancer (mod-
erate differentiated squamous cell carcinoma). A CT
scan showed a reccurent tumor in the uppermediasti-
num, and chemoradiation therapy was started with
500 mg/m2 of 5-FU and 20 mg/m2 of cisplatin (CDDP)
for five days aweek and 6mg/m2 ofmitomycin (MMC)
once a week. Focal irradiation at 2 Gy/day (total of 50
Gy) was also performed. After completion of the 2-week
chemotherapy, he started to feel left back pain. The
cause of the pain could not be confirmed clinically by
X rays or spinal MRI. Because of renal dysfunction
(BUN/CRNN, 84.4/2.4) due to severe heart failure,
continuous hemofiltration therapy (CHF) with 10000
U/day of heparin was performed for 2 weeks. The he-
moglobin level gradually decreased during the CHF,
and the patient was followed conservatively. On the
15th day after startingCHF,hecomplainedof progressive
left abdominal pain and fullness. Physical examination
demonstrated a firm, tender mass in the left flank.
Hemoglobin level had decreased to 5.7g/dl.WBCwas
11900/µl and platelet count was 10.1×104/µl, but the
prothrombin time was prolonged by only15.1% (aver-
age : 80-120). Intra-abdominal hemorrhage was sus-
pected and abdominal US was performed. US showed
a mixed high-echoic mass in the left pelvis and as-
cites in Douglas’ pouch (Fig. 1A). A CT scan without
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a contrast-enhancing agent demonstrated an enlarged
left ileopsoas muscle with mixed density and a cap-
sulated cystic mass within the left psoas muscle and
posterior pararenal space (Fig. 1 B, C). The diagnosis
of retroperitoneal hematoma was confirmed by these
CT findings. The patient was treated conservatively with
a change in drugs fromheparin to nafamostat mesilate
(futhan), but the hemorrhage repeated again, and he
finally died due to severe heart and renal failure.
Patient 2 :
A 70-year-old male was transferred to our hospital
with the diagnosis of panperitonitis due to perforation
of the sigmoid colon. The sigmoid colon was resected,
and pathological examination revealed an adenocar-
cinoma. He also had a history of mitral valve replace-
ment about twenty years ago and had continuedmedi-
cation with warfarin. About one month after admission,
intra-arterial injection of 5-FU (at 1250mg/m2 per week)
was started for multiple liver metastases, confirmed by
CT. After the completion of 4 cycles of 5-FU treatment,
he felt severe lumbago. The next day, he vomited fre-
quently, and his blood pressure dropped to 70mmHg.
Hemoglobin level decreased from 9.6 to 6.9g/dl within
a day. WBC was 22500/µl and platelet count was 25.7×
104/µl. Prothrombin time (PT) and International Nor-
malized Ratio (INR) could not bemeasured because of
the lack of fibrinogen. Abdominal US revealed amixed
echo lesion within the psoas muscle and ascites (Fig.
2 A). CT scans with and without a contrast-enhancing
agent showed heterogeneous density masses within
the bilateral retroperitoneal space (Fig. 2B,C)withslight
leakage of contrast medium from the left psoasmuscle
(Fig.2 C). Warfarin therapy was withheld, and the pa-
tient was treated conservatively for 2 weeks. Three days
after restarting warfarin therapy, a transient ischemic
attack occurred, and treatment was changed from intra-
arterial injection of 5-FU to peroral administration of
UFT.
Fig 1．Patient 1.
(A) Abdominal US showed a heterogeneous high-echoic pelvic mass representing hematomas (arrow) and ascites in
Douglas’ pouch.
A CT scan without a contrast-enhancing agent demonstrated a mixed-density mass within the left psoas muscle (arrow):
(B)(C). Low-density hematomas were demonstrated within the left psoas muscle and left retroperitoneal space
(arrowhead).
Fig 2．Patient 2.
(A) Abdominal US showed a mixed-density mass within the ileopsoas muscle.
(B) A plain CT scan showed bilateral mixed-density retroperitoneal masses and swelling of ileopsoas muscles (arrow).
(C) A contrast-enhanced CT scan showed linear leakage of the contrast-enhancing agent within the hematoma (arrowhead).
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DISCUSSION
Retroperitoneal hematoma can occur in various situ-
ations such as trauma, rupture of an aortic aneurysm
and presence of a retroperitoneal tumor. CT clearly
demonstrates the site and extent of the hematoma
and is helpful for confirming the diagnosis. A high-
density lesion on unenhanced CT images indicates
a hematoma in the acute phase. Enhanced CT some-
times demonstrates extravasation of the intravenously
injected contrast-enhancing agent, consistent with acute
hemorrhage. Anticoagulant therapy is also one of the
causes of retroperitonealhematoma(1-5). Femoral nerve
disturbance is observed in 27-79% of such patients, the
disturbance being due to compression of the nerve by
the hematoma, commonly located in the ileopsoasmus-
cle (51-60%)(1). Retroperitoneal hematoma was also
suspected in our patients based on their clinical his-
tories and symptoms despite the absence of femoral
nerve disturbance. It has been reported that themortality
rate of patients with retroperitoneal hemorrhage who
received anticoagulant therapy (20%) was higher than
that of patients who did not receive anicoagulant therapy
(12%)(1). Conservative therapywith fresh-frozenplasma
and vitaminKmay be the first choice andcanbe followed
by surgery and intervention for persistenthemorrhage.
Choo reported the use of transcatheter embolization
for a patient with retroperitoneal hematoma who had
undergone anticoagulant therapy (11). Detection of
a bleeding artery is difficult because of the complexity
of the blood supply. Indication for interventional pro-
cedures such asembolizationandpercutaneousdrainage
remains unclear. Percutaneous drainagemightbeuseful
for patients such as patient 1 who show focal low den-
sities in the hematoma on CT images.
The combination of 5-FU and warfarin is known
to prolong PT for several weeks from the initiation of
5-FU treatment (6-10). Although the mechanism of
the interaction is unclear, it has been postulated that
5-FU interferes with the synthesis ofhepatic cytochrome
P-4502C9, the enzyme that principally metabolizes
warfarin by 7-and 6-hydroxylation (6, 7). Our patients
were also thought to have been affected by this inter-
action. It is difficult to determine the appropriate dose
of warfarin to be used in combinationwith 5-FU.Kolesar
reported 5 patientswhorequiredwarfarindose reduction
(mean reduction of 44%) regardless of the 5-FUregimen
(8). They recommended weekly PT and INR monitor-
ing for all patients undergoingwarfarin and 5-FU ther-
apy. In our cases, retroperitoneal hemorrhageoccurred
before the first PT examination, indicating the impor-
tance of PT examination within one week after starting
combination therapy.
It is sometimesdifficult todetermine thebest treatment
option for patients withmajor hemorrhage. Ananthas-
ubramaniam reported that none of twenty-eight patients
with prosthetic heart valves had thromboembolic com-
plications despite discontinuationof anticoagulant ther-
apy for a mean period of 15±4 days (12). One of our
patients in whom warfarin therapy was discontinued
for 14 days had a transient ischemic attack.
We should be aware of this interaction of 5-FU and
warfarin and regularly monitor PT. CT is useful for
evaluation of retroperitoneal hematoma.
CONCLUSION
Wehave described two cases of retroperitoneal hema-
toma in patients who underwent combination therapy
with warfarin and 5-FU. We should be aware of the in-
teraction of 5-FU and warfarin and the importance of
monitoring PT. Retroperitoneal hemorrhage might
occur in patients receiving combination therapy, and
a CT scan is useful for diagnosis and for determining
the extent of a hematoma.
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